Human Growth Hormone: The Complete Guide

Disclaimer: Pharmaceutical human growth hormone (somatropin) is a prescription-only medication in the UK. Growth hormone deficiency is a recognised clinical condition treated by the NHS and private endocrinologists. Off-label use for anti-ageing or performance is not a licensed indication. This article is educational. It does not constitute medical advice.

What Growth Hormone Actually Is

Growth hormone (GH), also called somatotropin, is a 191-amino acid peptide produced by somatotroph cells in the anterior pituitary gland. It is one of the most important anabolic hormones in the body — not in the narrow "muscle building" sense that the word "anabolic" has acquired online, but in the fundamental biological sense: growth hormone is involved in protein synthesis, fat metabolism, glucose regulation, bone density maintenance, tissue repair, immune function, and cellular regeneration.

It is not primarily a muscle-building hormone in adults. That understanding is a distortion of GH's actual physiology.

The GH Axis: How It Works

Growth hormone does not act in isolation. It is the centrepiece of a regulated axis:

Hypothalamus → Pituitary → Liver/Peripheral Tissues

The hypothalamus releases two opposing regulators:
- GHRH (Growth Hormone Releasing Hormone) — stimulates GH release
- Somatostatin — inhibits GH release The balance between these determines how much GH the pituitary secretes.
The anterior pituitary releases GH in pulses — not continuously. In healthy adults, the largest GH pulse occurs during slow-wave (deep) sleep, approximately 60–90 minutes after sleep onset. There are also smaller pulses during exercise, fasting, and throughout the day.
GH acts directly on tissues and also signals the liver to produce IGF-1 (Insulin-like Growth Factor 1). IGF-1 mediates many of GH's effects — it is the primary anabolic signal downstream of GH, responsible for tissue growth and protein synthesis.
IGF-1 (and GH itself) feeds back to the hypothalamus and pituitary to suppress further GH release — the negative feedback loop.

The pulsatile nature is important: GH must be secreted in pulses for normal physiology. Continuous GH elevation desensitises GH receptors over time. This is why GH secretagogue protocols that preserve pulsatility (CJC-1295 without DAC + Ipamorelin) are preferred over those that maintain constant elevation (CJC-1295 with DAC).

The Age-Related Decline: Somatopause

GH production declines with age in a process sometimes called somatopause (analogous to menopause/andropause for the GH axis). Key data points:

GH secretion peaks during puberty and early adulthood
After age 30, GH secretion declines by approximately 15% per decade
By age 60, many adults have GH pulse amplitude and frequency comparable to clinically deficient younger adults
IGF-1 declines in parallel — a convenient and more stable marker for the GH axis (GH itself fluctuates minute-to-minute; IGF-1 reflects average GH activity over days to weeks)

The consequences of somatopause are gradual and overlap significantly with general ageing: increased visceral adiposity, reduced lean muscle mass, reduced bone density, impaired wound healing, reduced exercise capacity, poorer sleep architecture.

The question is whether this age-related GH decline is itself the cause of these changes — or whether it co-occurs with them. The distinction matters for treatment decisions.

Pharmaceutical Growth Hormone: Somatropin

Synthetic human growth hormone (somatropin) is bioidentical to endogenous GH — 191 amino acids, identical structure. It is manufactured through recombinant DNA technology (the same technology used to make insulin).

Licensed Clinical Applications

Growth Hormone Deficiency (GHD) in adults: The best-supported adult indication. Adult GHD (caused by pituitary tumour, surgery, radiation, or idiopathic causes) is a recognised clinical syndrome with specific diagnostic criteria. Treatment with somatropin in confirmed GHD:

Reduces visceral fat
Improves lean mass
Improves bone density
Improves quality of life scores
Normalises lipid profile in many patients

This is the clearest indication and has the strongest evidence base. [Source: Molitch et al., 2011 — Evaluation and treatment of adult growth hormone deficiency — Journal of Clinical Endocrinology & Metabolism]

HIV wasting / AIDS wasting syndrome: GH improves lean mass in HIV patients with wasting. FDA-approved for this indication (Serostim).

Short bowel syndrome: GH improves intestinal absorption in SBS patients. FDA-approved (Zorbtive).

Paediatric growth failure: Multiple approved paediatric indications — the historically primary use of pharmaceutical GH.

Off-Label Use in Adults: What the Evidence Actually Shows

The use of GH in adults without confirmed deficiency — for anti-ageing, body composition, or performance — has been studied and the results are more nuanced than either proponents or detractors claim.

A 1990 NEJM study by Rudman et al. showed significant improvements in lean mass, reduced body fat, and improved skin thickness in older men treated with GH. This study sparked enormous interest in GH as an anti-ageing therapy. [Source: Rudman et al., 1990 — Effects of human growth hormone in men over 60 years old — NEJM]

What subsequent research showed:

A 2007 Annals of Internal Medicine meta-analysis of 31 GH studies in older adults found: modest improvements in body composition (increased lean mass, reduced fat mass), minimal improvement in strength, significant side effects, and no evidence of improvement in functional outcomes (what matters for actual quality of life). [Source: Liu et al., 2007 — Systematic review: the effects of growth hormone on athletic performance — Annals of Internal Medicine]

The honest summary of GH in non-deficient adults: body composition changes are real but modest; performance and functional improvements are not well-supported; side effect burden is significant; cost is very high.

Side Effects of Pharmaceutical GH

Understanding GH side effects requires distinguishing between dose-dependent effects (which are predictable and manageable at appropriate therapeutic doses) and serious risks at excessive doses.

Dose-Dependent, Usually Manageable

Water retention / oedema: GH increases sodium and water retention. Peripheral oedema, particularly in hands and feet, is common, especially early in treatment. Reduces with dose reduction or time.
Joint pain (arthralgia) and carpal tunnel syndrome: Fluid retention and GH's effects on connective tissue can cause joint discomfort and median nerve compression. Carpal tunnel is among the more commonly reported side effects.
Insulin resistance: GH is counter-regulatory to insulin — it raises blood glucose. At higher doses or with longer use, GH can cause significant insulin resistance and elevated fasting blood glucose. Monitoring is essential.
Headaches: Common early in treatment, usually transient.

More Serious Concerns

IGF-1 elevation and cancer risk: IGF-1 is a potent growth factor. Elevated IGF-1 promotes cellular proliferation. Epidemiological studies show associations between elevated circulating IGF-1 and increased risk of colorectal, prostate, and breast cancers. [Source: Renehan et al., 2004 — Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk — Lancet]

The interpretation: this does not mean GH treatment causes cancer. Patients with known active malignancy are contraindicated for GH treatment. Men with a strong family history of prostate cancer should have this consideration weighed explicitly in any decision about GH or GH secretagogue use.

Acromegaly at excessive doses: Acromegaly is the pathological condition caused by chronic GH excess. Features: coarsening of facial features, jaw protrusion, enlargement of hands and feet, organomegaly. It is a serious condition with cardiovascular and metabolic consequences. This occurs with genuine GH excess — doses far above therapeutic — but it is the extreme end of the GH risk spectrum that users should be aware of.

IGF-1 as the Primary Monitoring Marker

IGF-1 is the most practical proxy for the GH axis because:

It is stable in the blood (unlike GH, which is pulsatile)
It reflects average GH secretory activity over days to weeks
It can be measured from a standard blood draw
It is the downstream effector of most GH actions

Target on GH therapy: Upper quarter of the age-adjusted reference range. IGF-1 above the upper limit of the reference range (>1.5 SDS above mean) is associated with the side effect and risk profile above.

Medichecks offers an IGF-1 test in the UK (approximately £45–65 standalone, or included in more comprehensive panels).

Growth Hormone Secretagogues: The Practical Alternative

For most men interested in GH axis optimisation, pharmaceutical GH is:

Prescription-only (not accessible without clinical diagnosis)
Expensive (£1,000+/month outside NHS)
Associated with significant side effect burden at doses that produce meaningful effects

GH secretagogues — compounds that stimulate the pituitary's own GH production — are the more accessible and arguably more physiologically appropriate approach.

For the full peptide reference covering CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, and MK-677, see the dedicated peptides reference guide on this site.

Key Distinctions

Pharmaceutical GH vs. Secretagogues:

The physiological argument for secretagogues:

The GH axis evolved with pulsatile signalling for a reason. Exogenous GH floods the system continuously, bypasses the feedback loops, and suppresses endogenous production (the pituitary detects high GH and downregulates its own output). A secretagogue works with the axis — it amplifies the pituitary's own pulses rather than replacing them.

This is why protocols using CJC-1295 (no DAC, short-acting GHRH analogue) combined with Ipamorelin (selective GHRP) are preferred: they produce a single amplified GH pulse at the time of injection, preserving the natural pulsatile pattern, then clear before the next injection.

The Safety Concern Specific to GH and Secretagogues

IGF-1 Monitoring Is Not Optional

Whether using pharmaceutical GH or secretagogues, IGF-1 should be:

Tested at baseline before starting
Re-tested at 8–12 weeks
Kept within the upper quarter of the age-adjusted reference range

Driving IGF-1 above the reference range — even through well-intentioned "optimisation" protocols — moves into the risk territory described above.

Insulin Resistance Management

For men using GH secretagogues long-term, fasting blood glucose and HbA1c should be monitored at baseline and at 3–6 month intervals. MK-677 is most associated with glucose elevation. CJC-1295/Ipamorelin protocols show less glucose impact at typical doses, but monitoring is still appropriate.

Who Should Not Use GH or GH Secretagogues

Active malignancy (any form — GH axis stimulation is contraindicated)
Significant diabetic or pre-diabetic status without medical oversight
Acromegalic features (suggests pre-existing GH excess)
Known or suspected pituitary tumour

What GH Will and Won't Do: Setting Realistic Expectations

This is important because the mythology around GH — particularly in non-medical communities — significantly overstates its effects.

What optimised GH axis activity will do (evidence-supported in the relevant population):

Improve sleep quality, particularly deep sleep architecture (the largest GH pulse occurs in deep sleep; improving GH pulsatility during sleep is likely the most impactful benefit for most men)
Support body composition — modest visceral fat reduction, lean mass preservation (not building — preservation)
Support tissue healing and recovery
Improve skin texture and thickness over months
Improve energy and sense of wellbeing in men with genuinely suppressed GH axis

What it will not do:

Produce dramatic muscle gain in men with normal GH levels — the evidence is clear that GH without supraphysiological doses does not significantly increase muscle mass in non-deficient adults
Replace the fundamentals — training, protein, sleep, testosterone optimisation
Reverse ageing in any direct sense

The men who look dramatically different from GH use are typically combining GH with other compounds (testosterone, insulin in some cases), training at a high level, and consuming significant calories. Attributing the results to GH alone is misleading.

Practical Protocol Summary (Where Clinically Supervised Use Applies)

CJC-1295 (No DAC) + Ipamorelin — GH Optimisation Protocol

Timing: 30–60 minutes before sleep (fasted state, 2–3 hours after last meal)
Dose: 200mcg CJC-1295 (no DAC) + 200mcg Ipamorelin, combined in same injection
Route: Subcutaneous
Duration: 3–6 months, with IGF-1 testing at 8–12 weeks
Monitoring: IGF-1, fasting blood glucose

Rationale: The sleep injection captures and amplifies the natural overnight GH pulse — the largest pulse in the daily GH secretory pattern. The synergistic GHRH+GHRP combination produces a GH pulse 2–10× larger than either agent alone.

The Short Version

Growth hormone is a complex, multi-system hormone that declines gradually from middle age. Pharmaceutical GH has strong evidence in confirmed deficiency and specific clinical conditions; the evidence in non-deficient adults is real but modest for body composition and weak for functional outcomes. Side effects include insulin resistance, fluid retention, carpal tunnel, and elevated IGF-1 with associated cancer biology concerns. GH secretagogues (CJC-1295/Ipamorelin) are the practical alternative for most men — more physiologically appropriate (pulsatile), more accessible, lower cost, and milder side effect profile. IGF-1 monitoring is essential regardless of approach. The fundamentals — sleep quality, body composition, testosterone optimisation — produce the GH axis improvements that matter most for most men before any pharmaceutical intervention is warranted.